Interpore’s $30 Mil. Spinal Business Provides Backbone For Growth
This article was originally published in The Gray Sheet
Executive Summary
Interpore Cross International's C-TEK anterior cervical plate and Synergy lower back and deformity systems are driving a big jump in the company's spinal product line: sales of spinal products climbed 49% to $8.4 mil. in the final quarter of 2001
You may also be interested in...
Interpore Cross
Spinal implant maker will acquire AOM-CDO system for placing reinforcing substances inside bony structures such as spinal vertebrae through a $21.3 mil. agreement with privately held OsteoMedix, announced May 31. Introduced in mid-2000, the minimally invasive device allows treatment of pain from vertebral compression fractures, according to Interpore. Expected to close by July 31, the deal calls for Interpore to pay $8 mil. in cash and about $2.4 mil. in Interpore stock, which closed May 30 at $5.53 per share. AOM had about $1.2 mil. in sales in 2000
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.